The Netherlands Pharmaceutical Market report segments the industry into ATC/Therapeutic Class (Alimentary Tract and Metabolisma, Blood and Blood-forming Organs, Cardiovascular System, Dermatological Drugs, Genitourinary System and Reproductive Hormones, Systemic Hormonal Preparations, Excluding Reproductive Hormones and Insulins, Antiinfectives for Systemic Use, and more), Mode of Dispensing (Prescription, OTC).

[240+ Pages Report] The global Pharmaceutical market size is expected to grow from USD 1,482.4 million to USD 2,067.36 million by 2028, at a CAGR of 5.70% from 2022-2028

The Sweden Pharmaceutical Market Report Segments the Industry Into by ATC/Therapeutic Class (Cardiovascular System, Dermatological, Genito Urinary System and Sex Hormones, Anti-Infective for Systemic Use, Antineoplastic and Immunomodulating Agents, Musculoskeletal System, Nervous System, Respiratory System, and More), by Drug Type (Branded, Generic), and by Prescription Type (Prescription Drugs (Rx), Over the Counter (OTC) Drugs).

Brand name pharmaceutical manufacturers in the US are some of the most lucrative in the world. Consumers in the US use and spend more on prescription drugs than any other country, making manufacturers central to meeting this demand and supporting public health. This role was evident during the COVID-19 pandemic, as brand name pharma producers researched, produced and distributed vital vaccines in record time. Aside from vaccine development, domestic manufacturers can attribute rising spending on brand name drugs to several factors, including an aging population, expanding health coverage, new drug approvals and medical advances in expensive specialty areas like rare diseases and oncology. Still, mounting scrutiny facing brand name pharma makers focuses on pricing policies and patent protections, suggesting that the industry’s strong performance indicates monopolistic practices and price hikes rather than rising prescription drug use. In all, revenue has been growing at a CAGR of 5.8% over the past five years to an estimated $302.9 billion, including expected growth of 3.7% in 2025. One of the most notable pieces of regulation to date impacting brand name pharma producers is the Inflation Reduction Act (IRA). Passed in 2022, the IRA introduces multiple provisions impacting the industry, permanently reshaping how pharmaceutical manufacturers will operate. Key provisions of the IRA include Medicare’s ability to negotiate drug prices, rebates for excessive price increases and an out-of-pocket spending cap. While a substantial body of criticism and legal challenges surrounding the IRA exist, it marks the movement to lower drug spending for patients and the federal government. While brand name pharma manufacturers will navigate an evolving environment, the industry’s performance will remain robust. Ongoing R&D investments will yield new, innovative therapies to address unmet needs, bolstering product pipelines. At the same time, an increasing prevalence of chronic illness and a growing number of over 65 adults will support a steep demand for prescription drugs. Merger and acquisition activity seen in recent years won’t slow as incumbents look for ways to diversify pipelines, access new technologies or reach new markets as pressures from patent cliffs and the regulatory landscape mount. Still, revenue growth will be strong, increasing at a CAGR of 3.4% to an estimated $358.1 billion over the next five years

The China pharmaceutical intermediate market is projected to be valued at USD 9,309.7 million in 2025 and is anticipated to witness a steady expansion at a CAGR of 6.4%, reaching USD 17,276.3 million by 2035.

Pharmaceutical Industry Software Market Outlook

The global pharmaceutical industry software market size was valued at approximately USD 4.5 billion in 2023 and is expected to reach USD 8.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.8% during the forecast period. This growth is driven by an increasing demand for efficient data management solutions, technological advancements, and regulatory compliance requirements within the pharmaceutical sector. The market is propelled by the need for enhanced operational efficiency and data-driven decision-making, which are critical in the highly competitive pharmaceutical landscape. Additionally, the ongoing digital transformation within the industry and the adoption of advanced technologies such as AI, machine learning, and blockchain are expected to further fuel the market's growth.

One of the major growth factors contributing to the expansion of the pharmaceutical industry software market is the increasing complexity and volume of data generated in pharmaceutical operations. As companies strive to accelerate drug discovery and development while ensuring compliance with stringent regulatory standards, the need for robust software solutions to manage, analyze, and interpret vast amounts of data becomes paramount. Laboratory Information Management Systems (LIMS) and Regulatory Compliance Software have become essential tools, providing comprehensive data management capabilities and ensuring adherence to regulations such as FDA and EMA guidelines. Moreover, the growing trend of personalized medicine and the increasing focus on real-world data and evidence have further underscored the importance of efficient data management solutions in the pharmaceutical sector.

Technological advancements and innovations in pharmaceutical industry software are also key drivers of market growth. The integration of artificial intelligence, machine learning, and other advanced analytics capabilities into software solutions has transformed the pharmaceutical landscape. These technologies enable companies to improve data accuracy, optimize clinical trials, and streamline regulatory submissions. Furthermore, the adoption of cloud-based solutions has gained significant traction, offering scalability, flexibility, and cost-effectiveness to pharmaceutical companies. Cloud-based software solutions facilitate seamless data sharing across global teams, enhance collaboration, and reduce the need for extensive IT infrastructure, making them an attractive option for companies of all sizes.

The rise of precision medicine and the increasing importance of patient-centric approaches have further fueled the demand for pharmaceutical industry software. As companies aim to deliver targeted therapies and improve patient outcomes, software solutions that support these initiatives are gaining prominence. Clinical Trial Management Systems (CTMS) and Quality Management Systems (QMS) play a crucial role in optimizing clinical trial operations, ensuring data integrity, and maintaining product quality throughout the lifecycle. Additionally, the growing emphasis on pharmacovigilance and risk management has led to the adoption of specialized software solutions that enable companies to monitor and mitigate potential risks associated with their products.

From a regional perspective, North America is expected to dominate the pharmaceutical industry software market during the forecast period, owing to the presence of a well-established pharmaceutical industry, advanced healthcare infrastructure, and favorable government initiatives supporting digital transformation. Europe is also anticipated to witness significant growth, driven by stringent regulatory requirements and increasing investments in research and development activities. Meanwhile, the Asia Pacific region is projected to experience the highest growth rate, attributed to the rapidly expanding pharmaceutical sector, growing healthcare expenditure, and increasing adoption of digital technologies in emerging economies such as China and India.

Software Type Analysis

The software type segment of the pharmaceutical industry software market encompasses a diverse array of solutions tailored to address specific requirements within the industry. Laboratory Information Management Systems (LIMS) stand out as a vital component, offering functionalities that streamline laboratory workflows, automate data collection, and enhance data integrity. By facilitating efficient sample management and enabling real-time data analysis, LIMS play a critical role in accelerating drug discovery and development processes. The market for LIMS is buoyed by the gr

The pharmaceutical packaging market size is estimated to be worth USD 112.3 billion in 2025 and is anticipated to reach a value of USD 153.9 billion by 2035. Sales are projected to rise at a CAGR of 3.2% over the forecast period between 2025 and 2035. The revenue generated by pharmaceutical packaging in 2024 was USD 109.5 billion.

Semi Annual Market Update

Country-wise Insights

Category-wise Insights

Pharmaceutical Software Market Outlook

According to our latest research, the global pharmaceutical software market size reached USD 9.8 billion in 2024, reflecting robust growth across all major regions. The market is projected to expand at a CAGR of 12.1% during the forecast period, reaching an estimated USD 27.2 billion by 2033. This remarkable growth is fueled by the increasing digitization of pharmaceutical operations, stringent regulatory requirements, and the ongoing need for enhanced data integrity and process optimization in the life sciences sector.

One of the primary growth drivers for the pharmaceutical software market is the rising complexity of drug development and manufacturing processes. As pharmaceutical companies face mounting pressure to accelerate time-to-market for new therapies, software solutions are playing a pivotal role in streamlining operations, from clinical trial management to manufacturing execution and regulatory compliance. The integration of advanced analytics, artificial intelligence, and cloud computing into pharmaceutical software platforms has enabled organizations to derive actionable insights from vast datasets, improve decision-making, and minimize costly errors. This digital transformation is not only optimizing resource allocation but also ensuring that companies remain agile in the face of evolving scientific and regulatory landscapes.

Another significant factor contributing to the expansion of the pharmaceutical software market is the increasing emphasis on regulatory compliance. Regulatory agencies worldwide, such as the FDA and EMA, have established rigorous guidelines for data integrity, traceability, and quality assurance. Pharmaceutical software solutions are essential for maintaining compliance with these standards, automating documentation, and facilitating transparent audit trails. Furthermore, the growing trend of outsourcing drug development activities to contract research organizations (CROs) and the adoption of collaborative research models have amplified the demand for secure, interoperable software platforms that can seamlessly integrate with diverse systems and stakeholders across the pharmaceutical value chain.

The surge in demand for efficient supply chain management and inventory control is also driving the adoption of pharmaceutical software. The COVID-19 pandemic exposed vulnerabilities in global pharmaceutical supply chains, highlighting the need for real-time visibility, predictive analytics, and risk mitigation strategies. Software solutions tailored for inventory management, logistics, and distribution are enabling pharmaceutical companies to optimize stock levels, reduce wastage, and respond swiftly to market fluctuations. These capabilities are particularly critical in the context of personalized medicine and complex biologics, where supply chain agility and precision are paramount.

From a regional perspective, North America continues to dominate the pharmaceutical software market, accounting for the largest share in 2024, followed closely by Europe and Asia Pacific. The United States, in particular, benefits from a highly developed pharmaceutical infrastructure, substantial R&D investments, and a proactive regulatory environment that encourages digital innovation. Meanwhile, Asia Pacific is emerging as the fastest-growing region, driven by expanding pharmaceutical manufacturing capabilities, rising healthcare expenditures, and increasing adoption of digital health technologies in countries such as China, India, and Japan. Europe remains a key market, supported by strong regulatory frameworks and a tradition of pharmaceutical excellence. Latin America and the Middle East & Africa are also witnessing gradual adoption, propelled by healthcare modernization initiatives and growing awareness of the benefits of pharmaceutical software.

Solution Type Analysis

The pharmaceutical software market is segmented by solution type into clinical trial management, regulatory compliance, quality

Snapshot img

Specialty Pharmaceuticals Market Size 2024-2028

The specialty pharmaceuticals market size is forecast to increase by USD 406.6 billion, at a CAGR of 13.64% between 2023 and 2028.

The market is experiencing significant growth, driven by the increasing demand for research and development due to escalating government healthcare expenditure. This investment in R&D is leading to the introduction of innovative therapies, catering to unmet medical needs and enhancing patient outcomes. However, the market is not without challenges. The stringent regulations imposed by regulatory bodies present a formidable hurdle, requiring companies to adhere to rigorous standards and lengthy approval processes. Moreover, the aging population is fueling the demand for specialty pharmaceuticals, as older adults often require complex and costly treatments for chronic conditions.
Companies seeking to capitalize on this market opportunity must navigate these regulatory obstacles and invest in research and development to stay competitive and meet the evolving needs of an aging population.

What will be the Size of the Specialty Pharmaceuticals Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free Sample

The market continues to evolve, shaped by various market dynamics and applications across diverse sectors. Health economics plays a significant role, as contract manufacturing organizations optimize production costs and healthcare professionals navigate complex patient access issues. Drug interactions and adverse events necessitate robust safety monitoring and regulatory affairs. Pricing strategies for orphan drugs and infectious diseases are subject to ongoing debate, while targeted therapy and pharmaceutical research drive innovation in personalized medicine. Intellectual property rights and patent expiry impact market access and supply chain management. Formulation development, stability studies, and quality control are essential components of the drug development process.

Neurological, cardiovascular, and respiratory diseases are among the areas of focus in this dynamic industry. Precision medicine and value-based healthcare are emerging trends, while disease management and rare diseases remain critical areas of concern. Analytical chemistry, regulatory compliance, and packaging materials are integral to ensuring product efficacy and patient safety. The ongoing unfolding of market activities reveals evolving patterns in drug metabolism, clinical pharmacology, and regulatory landscapes.

How is this Specialty Pharmaceuticals Industry segmented?

The specialty pharmaceuticals industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Application

  Oncology
  Multiple sclerosis
  Inflammatory conditions
  Infectious diseases
  Others


Distribution Channel

  Offline
  Online


Geography

  North America

    US


  Europe

    Germany
    UK


  APAC

    China
    Japan


  Rest of World (ROW)

By Application Insights

The oncology segment is estimated to witness significant growth during the forecast period.

Oncology drugs, which target and destroy or inhibit the growth of cancer cells, are a crucial component of cancer treatment. These medications come in various forms, including chemotherapy treatment , targeted therapy, immunotherapy, and hormone therapy. The selection of the most effective drug and treatment plan depends on several factors, such as the cancer type and stage, the patient's overall health and medical history, potential drug interactions, and side effects. Healthcare professionals collaborate closely with patients and their families to determine the best treatment approach. Pharmaceutical research and development play a significant role in the creation of new oncology drugs, driven by intellectual property protections and advancements in fields like personalized medicine, disease management, and precision medicine.

The supply chain management of oncology drugs involves contract manufacturing, formulation development, and distribution networks. Quality control and regulatory affairs are essential components of the process, ensuring the safety and efficacy of these complex medications. Infectious diseases, such as HIV/AIDS and hepatitis, have also seen advancements in treatment through the development of targeted therapy and orphan drugs. Cardiovascular diseases, neurological diseases, respiratory diseases, and other conditions also benefit from ongoing pharmaceutical research and innovation. Value-based healthcare and pricing strategies are increasingly important considerations in the oncology drug market. Analytical che

The Germany Pharmaceutical Market Report is Segmented by Therapeutic Category (Anti-Infectives, Gastrointestinal, and More) and Drug Type (Prescription Drugs and OTC Drugs), Molecule Type (Small-Molecule, Biologic, and Biosimilar), Route of Administration (Oral, Inhalation, and More), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

The Pharmaceutical Data Management Software market has emerged as a critical component in the pharmaceutical industry, facilitating the efficient handling of vast amounts of data involved in drug development, clinical trials, and regulatory compliance. As the pharmaceutical sector continues to evolve with increasing

Pharmaceutical preparations manufacturing revenue is expected to contract at a compound annual rate of 0.7% over the five years through 2025-26 to £24.4 billion. The aftermath of the pandemic has raised demand for medicines as healthcare facilities work through patient backlogs. However, the surging Voluntary Scheme for Branded Medicines Pricing, Access and Growth rate has elevated the proportion of revenue returned to the NHS, constraining revenue. Moreover, global supply chain disruptions, particularly from tensions in the Middle East, have driven up active pharmaceutical ingredients (APIs) costs, impacting profitability. The UK's reputation as a leader in pharmaceutical manufacturing continues to support sales. Investment in R&D, alongside M&A activity, remains crucial for driving revenue, particularly for drugs with patent protection. However, Brexit-related complexities have added to the cost of exporting and importing, negatively impacting trade volumes. This is compounded by the emergence of cheaper foreign alternatives and higher trade barriers, weighing on revenue. Industry revenue is projected to decline by 1.2% in 2025-26, with profit nudging down to 8.5%.Revenue is forecast to climb at a compound annual rate of 0.7% to £25.3 billion over the five years through 2030-31. Continued investment in research and development will be vital for discovering new blockbuster drugs. Manufacturers are likely to leverage AI to streamline costs, safeguarding profit. Sales of vitamins and natural medications are expected to climb amid growing health consciousness. However, positive revenue forecasts are threatened by trade wars in 2025-26. The introduction of tariffs will weigh on UK exports as UK pharmaceuticals become more expensive in the US. The cost of APIs may rise as key producers hike prices to combat falling sales from the US, elevating purchase costs and reducing profitability within the industry.

The Iceland Pharmaceutical Market report segments the industry into By ATC/Therapeutic Class (Value) (Alimentary Tract And Metabolism, Blood And Blood Forming Organs, Cardiovascular System, Dermatological Drugs, Genitourinary System And Reproductive Hormones, Systemic Hormonal Preparations, Excluding Reproductive Hormones And Insulins, Antiinfectives For Systemic Use, Antineoplastic And Immunomodulating Agents, and more).

The High Purity Quartz (HPQ) and silica market for the pharmaceutical industry is rapidly evolving, driven by the increasing demand for high-quality raw materials that meet stringent regulatory requirements. HPQ stands out as a crucial ingredient in the production of various pharmaceutical formulations due to its ex

Market Outlook The global temperature-controlled packaging pharmaceutical market size was valued at $11,930 million in 2025 and is projected to grow at a CAGR of 9.2% from 2025 to 2033. This growth is primarily attributed to the increasing demand for temperature-sensitive pharmaceutical products, such as vaccines, biological drugs, and regenerative medicine. Additionally, the growing need for reliable and efficient transportation of these products, coupled with advancements in packaging technologies, is further driving market growth. Key Drivers and Trends The rising prevalence of chronic diseases, the expanding biopharmaceutical industry, and the globalization of pharmaceutical supply chains are the key drivers of the temperature-controlled packaging pharmaceutical market. The adoption of active and passive temperature-controlled packaging systems is becoming popular due to their ability to maintain specific temperature ranges during transit and storage. Furthermore, government regulations and international standards for the transportation of temperature-sensitive pharmaceuticals are promoting the adoption of these packaging solutions, contributing to the market's overall growth potential. Recent developments include: In 2022, CCT acquired Packaging Technology Group Inc (US). This acquisition will provide environmentally friendly and innovative thermal packaging solutions for the life sciences industry. In 2021, UPS opened a new cold chain packaging center in Kentucky (US) to serve its global healthcare logistics customers. This expansion will help manage the growing number of temperature-sensitive biologic drugs and currently developing cell and gene treatments. In 2020, Sonoco ThermoSafe signed an agreement with Asiana Airlines Inc. (Seoul) for leasing the new Pegasus ULD temperature-controlled bulk shipping container. This agreement will provide pharmaceutical freight forwarders access to Pegasus ULD containers directly from Asiana Airlines. . Notable trends are: Growth In The Pharmaceutical Industry Supplementing Sales To The Significant Extent.

The size of the Denmark Pharmaceutical Industry market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 3.40% during the forecast period.Denmark's pharmaceutical industry is one of the largest in the world and ranks high on innovation, top-level research, and quality products. An exceptionally strong tradition is provided by pharmaceuticals in such areas as diabetes, obesity, and neurodegenerative diseases. Among the key industry players in Denmark are Novo Nordisk, already established as one of the world's leaders in diabetes care, and Lundbeck, another global pharmaceutical company, focusing mainly on brain diseases. In a state like Denmark, companies, along with small biotech firms numbering many, have much to contribute to the national economy and, indeed, to global health.Good regulatory environment, international standards of research institutes, and high-skilled workforce are add-on advantages of this industry in Denmark.There was the emphasis always on the basic research and development found in the country. This led to the discovery of many new drugs and medicines, and life became better for millions around the world. In addition, its strategic location in Europe and a robust logistics infrastructure have made Denmark an extremely sought-after headquarters for pharmaceutical manufacturing and distribution. Recent developments include: In July 2022, Bavarian Nordic, the Danish company is expanding its production capacity to 10 million doses of the monkeypox vaccine., In June 2022, Novo Nordisk A/S, a top global healthcare organization, and Echosens, a high-tech business providing liver diagnostic tools, entered into a partnership to promote early diagnosis of non-alcoholic steatohepatitis (NASH) and raise patient awareness of the condition.. Key drivers for this market are: Collaboration between Private and Public Sector, Rising Funding for Research and Development. Potential restraints include: High Tax Rates on Pharmaceutical Products. Notable trends are: Prescription Drugs (Rx) accounted for the Significant Share of the Total Pharmaceutical Sales in Denmark.

The leading company in the pharmaceutical industry in Romania in 2024 was Zentiva with a revenue of almost 1.6 billion Romanian lei, increasing it by 57.6 percent since 2021. It was followed by Terapia and Antibiotice.

The Pharmaceutical Grade Nervous Acid Products market is a critical segment of the broader pharmaceutical industry, significantly influencing drug formulation and therapeutic advancements. These products, which encompass a range of high-purity compounds essential for the synthesis of biologically active ingredients,

AI-Driven Pharma Sales Enablement Market Outlook

According to our latest research, the global AI-Driven Pharma Sales Enablement market size reached USD 1.82 billion in 2024, reflecting robust adoption across the pharmaceutical sector. The market is projected to expand at a CAGR of 21.4% from 2025 to 2033, reaching a forecasted value of USD 12.13 billion by 2033. This remarkable growth trajectory is driven by increasing digital transformation initiatives, the rising complexity of pharmaceutical sales processes, and the critical need for advanced analytics and automation to enhance sales performance and customer engagement in the healthcare industry.

One of the primary growth factors for the AI-Driven Pharma Sales Enablement market is the escalating demand for data-driven decision-making in pharmaceutical sales operations. As the pharmaceutical landscape becomes more competitive and regulated, organizations are leveraging AI-powered tools to streamline sales processes, improve targeting, and personalize customer interactions. These solutions are enabling sales teams to access real-time insights, automate routine tasks, and optimize engagement strategies, resulting in improved sales productivity and higher conversion rates. The integration of AI-driven analytics with customer relationship management (CRM) platforms is empowering pharma companies to harness vast datasets from multiple channels, thus facilitating informed decision-making and more effective sales enablement.

Another significant growth driver is the increasing focus on compliance and regulatory requirements within the pharmaceutical industry. AI-driven sales enablement platforms are designed to ensure that sales representatives adhere to industry regulations and company policies, reducing the risk of non-compliance. These platforms can automatically update sales content in line with regulatory changes, provide real-time training and onboarding, and monitor interactions to flag potential compliance issues. As regulatory scrutiny intensifies, especially in mature markets such as North America and Europe, pharmaceutical companies are investing heavily in AI-powered solutions to mitigate risks and maintain a competitive edge.

The rapid evolution of digital healthcare ecosystems is also fueling the adoption of AI-driven sales enablement solutions. The COVID-19 pandemic accelerated the shift towards remote engagement and virtual selling, prompting pharmaceutical companies to rethink their sales strategies. AI-powered platforms are now essential for supporting hybrid sales models, enabling seamless communication between sales teams, healthcare providers, and other stakeholders. The ability to deliver personalized content, provide actionable insights, and facilitate continuous learning is transforming the way pharma sales teams operate, driving sustained market growth. Furthermore, advancements in machine learning, natural language processing, and predictive analytics are expected to unlock new use cases and propel further innovation in this space.

From a regional perspective, North America is currently the largest market for AI-Driven Pharma Sales Enablement solutions, accounting for a significant share of global revenues in 2024. This dominance is attributed to the high concentration of leading pharmaceutical companies, advanced healthcare infrastructure, and strong emphasis on digital transformation. Europe follows closely, driven by stringent regulatory standards and increasing investments in healthcare technology. Meanwhile, the Asia Pacific region is emerging as a high-growth market, fueled by expanding pharmaceutical sectors in countries such as China and India, rising healthcare expenditures, and growing awareness of the benefits of AI-driven sales enablement. Latin America and the Middle East & Africa are also witnessing gradual adoption, supported by ongoing digitalization initiatives and government efforts to modernize healthcare delivery.

Component Analysis

The AI-Driven Pharma Sales Enablement market is segmented

Pharmaceuticals are a core segment of Ireland's economy, accounting for a leading share of national exports. Low corporate tax rates and generous research and development tax credits offered by the Irish state make the country a highly appealing location for multinational pharmaceutical manufacturers to base their European operations. Consequently, nine of the 10 largest pharmaceutical companies in the world have a presence in the country. Ireland is also the largest net exporter of pharmaceuticals in the EU, accounting for over 42.4% of all exports from the country, according to CSO data. Pharmaceutical preparations manufacturing revenue is expected to grow at a compound annual rate of 5.5% over the five years through 2024 to reach €70.8 billion. Pharmaceutical manufacturers have been supported by growth in export markets over the past few years as large multinationals have directed significant investment towards expanding operations in the country. Ireland's ageing population has also provided manufacturers with a steadily expanding source of domestic demand. Emerging technologies have also opened up niche segments for specialist start-ups, while the evolution of resistant bacteria and the resurgence of infections and viruses are raising demand for vaccines. The global COVID-19 pandemic, while causing a surge in demand for vaccines during its roll-out, has also led to a short-term drop in exports since 2023 as demand flat-lined. Industry revenue is forecast to rise at a compound annual rate of 4.6% over the five years through 2029, reaching €88.6 billion. Large investments planned by the industry's major companies to expand operations will support further growth in export markets, while the continued expansion and ageing of the Irish population will aid domestic demand. New avenues for growth are likely to include innovations in biotechnology, particularly in developing genetically tailored drugs and effective antibiotics to tackle growing levels of resistance. Rising life expectancy, growing awareness of the adverse health implications associated with obesity and greater emphasis on healthy lifestyles will be key drivers of growth over the next few years.